Capzimin, a pharmacological inhibitor of RPN11, alleviated NAFLD, NASH, and related metabolic disorders in mice while also lowering the lipid content of human hepatocytes in both 2D and 3D cultures (131). This evidence concerns the gene PSMD14 and metabolic dysfunction-associated steatotic liver disease.